Christine Messmer PC Invests $1.20 Million in Amgen Inc. $AMGN

Key Points

• Christine Messmer PC purchased a new position of 3,662 Amgen shares valued at approximately $1.20 million, about 0.8% of its portfolio and the firm's 27th-largest holding.
• Amgen announced an additional $300 million investment to expand and modernize its U.S. manufacturing footprint in Juncos, Puerto Rico, part of nearly $2 billion of U.S. manufacturing investment over the last year to boost capacity and supply resilience.
• Amgen beat Q results with $5.15 EPS versus $4.77 expected and $8.62 billion revenue, set FY2026 guidance of 21.700–23.100 EPS, and declared a quarterly dividend of $2.52 (3.1% yield).

Christine Messmer PC purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,662 shares of the medical research company's stock, valued at approximately $1,199,000. Amgen makes up approximately 0.8% of Christine Messmer PC's portfolio, making the stock its 27th biggest position.

Several other institutional investors have also modified their holdings of the company. Nordwand Advisors LLC boosted its stake in shares of Amgen by 1.2% during the 4th quarter. Nordwand Advisors LLC now owns 25,507 shares of the medical research company's stock worth $8,349,000 after acquiring an additional 305 shares in the last quarter. Highland Capital Management LLC purchased a new stake in shares of Amgen during the 4th quarter worth approximately $831,000. Alliance Wealth Advisors LLC UT boosted its stake in shares of Amgen by 7.3% during the 4th quarter. Alliance Wealth Advisors LLC UT now owns 798 shares of the medical research company's stock worth $261,000 after acquiring an additional 54 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Amgen by 3.2% during the 4th quarter. Principal Financial Group Inc. now owns 611,351 shares of the medical research company's stock worth $200,101,000 after acquiring an additional 18,791 shares in the last quarter. Finally, QRG Capital Management Inc. raised its position in shares of Amgen by 7.2% during the 4th quarter. QRG Capital Management Inc. now owns 78,354 shares of the medical research company's stock worth $25,646,000 after purchasing an additional 5,262 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced an additional $300 million investment to expand and modernize its U.S. manufacturing footprint in Juncos, Puerto Rico — part of nearly $2 billion of U.S. manufacturing investment over the last year; this strengthens capacity, supply resilience and long-term revenue support. AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR
• Neutral Sentiment: Coverage of the Puerto Rico expansion by major outlets (Reuters, Quartz) highlights the same investment news — useful for validation but not new catalyst beyond the company release. Amgen to invest additional $300 million to boost US manufacturing footprint
• Neutral Sentiment: Health-care stocks were softer in afternoon trade, which can amplify selling in large-cap biopharma names like Amgen even when company fundamentals are unchanged. Sector Update: Health Care Stocks Softer in Afternoon Trading
• Neutral Sentiment: A Zacks note flagged increased investor attention to AMGN; this signals higher scrutiny/flow but doesn’t itself imply directional catalyst. Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
• Negative Sentiment: Guggenheim trimmed its price target on AMGN to $340 from $351 and kept a Neutral rating — a modest cut but enough to pressure sentiment because it lowers upside expectations versus recent levels. Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Freedom Capital downgraded Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 12th. Jefferies Financial Group assumed coverage on Amgen in a research report on Tuesday, March 10th. They set a "hold" rating and a $350.00 price objective for the company. Truist Financial lifted their price objective on Amgen from $325.00 to $327.00 and gave the stock a "hold" rating in a research report on Friday. Sanford C. Bernstein downgraded Amgen from an "outperform" rating to a "market perform" rating and set a $335.00 price objective for the company. in a research report on Tuesday, January 20th. Finally, Royal Bank Of Canada lifted their price objective on Amgen from $360.00 to $370.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $357.12.

Amgen Trading Down 1.8%

Shares of AMGN opened at $323.85 on Tuesday. The stock has a fifty day moving average of $358.07 and a two-hundred day moving average of $341.12. The company has a debt-to-equity ratio of 5.65, a quick ratio of 0.90 and a current ratio of 1.26. The company has a market capitalization of $174.78 billion, a PE ratio of 22.54, a price-to-earnings-growth ratio of 3.24 and a beta of 0.44. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the firm posted $4.90 EPS. Amgen's revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts forecast that Amgen Inc. will post 22.28 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen's payout ratio is currently 70.15%.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.